Alembic Pharmaceuticals Gains USFDA Approval for Acne Treatment

Alembic Pharmaceuticals has obtained USFDA approval to market a generic Tretinoin Cream for treating acne vulgaris in the US. This product is a generic version of Retin-A Cream and holds a market size of USD 94 million. Alembic’s stock rose by 1.03% following the announcement.

Alembic Pharmaceuticals has announced it received final approval from the US Food & Drug Administration (USFDA) to sell a generic acne treatment in the United States.

The company will market Tretinoin Cream USP (0.025%), a therapeutic equivalent to Bausch Health's Retin-A Cream. The cream is designated for treating acne vulgaris.

According to analytics from IQVIA, Tretinoin Cream has a market value estimated at USD 94 million for the year ending June 2025. Following the announcement, Alembic's shares rose by 1.03%, trading at Rs 968.10 on the BSE.

(With inputs from agencies.)